Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 10Neoplasms 9Ovarian Neoplasms 8Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 6Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lung Neoplasms 5Leukemia 5Glioblastoma 5Colorectal Neoplasms 5Stomach Neoplasms 4Neuroblastoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Head and Neck Neoplasms 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Ovarian Epithelial 4Brain Neoplasms 4Recurrence 3Gliosarcoma 3Esophageal Neoplasms 3Breast Neoplasms 3Astrocytoma 3Advanced Solid Tumors 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mesothelioma, Malignant 2

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × Drug Therapy × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡